title: Post I-131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution?
abstract: BACKGROUND
  In patients with elevated serum thyroglobulin (Tg) and a negative whole-body scan (WBS), posttherapy scanning can reveal metastases in many cases and is therefore recommended. In contrast, the routine use of posttherapy scanning is questioned.
  
  
  METHODS
  One hundred six patients with differentiated thyroid carcinoma had pre- and posttherapy scanning, with metastatic uptake on the diagnostic scan and were divided into 2 groups: 60 patients assessed on first ablation after thyroidectomy and 46 patients with tumor persistence or recurrence after initial ablative therapy. Data modifying the disease stage or treatment were considered to be clinically relevant.
  
  
  RESULTS
  Posttherapy scanning on first ablation changed the disease stage in 8.3% of the patients and therapeutic approach in another 15%, and provided clinically relevant information for 26% of patients with 1 previous ablation. Even when excluding cases whose lesions were known by the time of the first postablative scan, the therapeutic approach was influenced by posttherapy scanning in 15.6% of the patients. Only 4 of 211 metastases detected on pretherapy WBS did not appear on postablative scans.
  
  
  CONCLUSIONS
  Posttherapy scanning provides important information, even in patients whose pretherapy WBS is positive for metastases, with this approach being useful both during the first ablation and subsequent treatment.
authors.affiliation: Endocrinology and Metabolism Service, Santa Casa de Belo Horizonte, Minas Gerais, Brazil. pedrorosario@globo.com
authors.forename: Pedro Wesley
authors.initials: PW
authors.lastname: Souza Rosário
authors.forename: Alvaro Luís
authors.initials: AL
authors.lastname: Barroso
authors.forename: Leonardo Lamego
authors.initials: LL
authors.lastname: Rezende
authors.forename: Eduardo Lanza
authors.initials: EL
authors.lastname: Padrão
authors.forename: Tales Alvarenga
authors.initials: TA
authors.lastname: Fagundes
authors.forename: Gustavo Cancela
authors.initials: GC
authors.lastname: Penna
authors.forename: Saulo
authors.initials: S
authors.lastname: Purisch
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000532:radiotherapy* / Q000556:secondary; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis / Q000000981:diagnostic imaging*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000627:therapeutic use; D015203:Reproducibility of Results; D018570:Risk Assessment / Q000379:methods*; D012307:Risk Factors; D012680:Sensitivity and Specificity; D013964:Thyroid Neoplasms / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000532:radiotherapy*; D016896:Treatment Outcome
chemical_list: D007457:Iodine Radioisotopes; D019275:Radiopharmaceuticals